(Reuters) -Merck said on Wednesday its therapy did not meet the main goal of a late-stage trial evaluating it in patients with a type of colorectal cancer.
The company said patients who took its experimental drug favezelimab in combination with Keytruda did not show significant improvement in overall survival compared to standard-of-care treatment.
The combination therapy is also being evaluated as a treatment for certain blood disorders and solid tumors.
(Reporting by Christy Santhosh; Editing by Varun H K and Shilpi Majumdar)
